SEARCH PLATELETNEWS.ORG
Faculty

Peter B. Berger, MD

Co-Chair

Glenn N. Levine, MD

Co-Chair
Poll
Do you prescribe dual antiplatelet therapy to patients presenting with acute coronary syndromes on admission?

Educational Links
You need to upgrade your Flash Player
Current Literature

Search Literature Reviews

 Categories
Browse Alphabetically by Author
A-D E-H I-L M-P Q-T U-Z

Keywords




Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non–ST-segment elevation acute coronary syndrome. Primary results of the DISPERSE-2 Trial

Cannon CP et al.
J Am Coll Cardiol.  2007;50:1844-1851.
  KEYWORDS: Acute Coronary Syndrome , Cardiovascular , Hemorrhage , Myocardial Infarction , Percutaneous Coronary Intervention , Pharmacologic Therapy

Eptifibatide Provides Additional Platelet Inhibition in Non–ST-Elevation Myocardial Infarction Patients Already Treated With Aspirin and Clopidogrel: Results of the Platelet Activity Extinction in Non–Q-Wave Myocardial Infarction With Aspirin, Clopidogrel, and Eptifibatide (PEACE) Study

Dalby et al.
J Am Coll Cardiol.   2004;43:162-168.
  KEYWORDS: Acute Coronary Syndrome , Aspirin , Cardiovascular , Myocardial Infarction , Percutaneous Coronary Intervention , Pharmacologic Therapy

Initial Experience With an Intravenous P2Y12 Platelet Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention: Results From a 2-Part, Phase II, Multicenter, Randomized, Placebo- and Active-Controlled Trial